Literature DB >> 14601057

DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.

Mary Jo Fackler1, Megan McVeigh, Ella Evron, Elizabeth Garrett, Jyoti Mehrotra, Kornelia Polyak, Saraswati Sukumar, Pedram Argani.   

Abstract

Little is known about epigenetic silencing of genes by promoter hypermethylation in lobular breast cancers. The promoter methylation status of 5 cancer-related genes (RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist) was evaluated in 2 types of lobular cancers, in situ (LCIS) and invasive lobular carcinomas (ILC) (n = 32), and compared to ductal in situ (DCIS) and invasive (IDC) breast cancers (n = 71). By using methylation-specific PCR (MSP), 100% of ILC and 69% of LCIS cases were found to have 1 or more hypermethylated genes among the panel of 5 genes (compared to 100% IDC and 95% of DCIS). Two or more hypermethylated genes were detected per tumor in 79% of invasive and 61% of in situ lobular carcinomas compared to 81% of IDC and 77% of DCIS. By contrast, DNA from nearly all normal reduction mammoplasty tissues (n = 8) was unmethylated for the 5 genes. The methylation profiles of lobular vs. ductal carcinomas with respect to RASSF1A, Cyclin D2, RARbeta, and Hin-1 genes were similar, suggesting that gene silencing by promoter hypermethylation is likely to be important in both groups of diseases. Distinctly different, Twist was hyper- methylated less often in ILC (16%, 3/19 cases) than in IDC (56%, 15/27 cases) (p = 0.01). These results suggest that these 2 types of tumors share many common methylation patterns and some molecular differences. Additional studies might lend further understanding into the etiology and clinical behavior of this tumor type. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14601057     DOI: 10.1002/ijc.11508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  95 in total

1.  Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Ayelet Avraham; Ronit Uhlmann; Aino Shperber; Miriam Birnbaum; Judith Sandbank; Avishay Sella; Saraswati Sukumar; Ella Evron
Journal:  Int J Cancer       Date:  2012-04-04       Impact factor: 7.396

Review 2.  The epigenetics of breast cancer.

Authors:  Jovana Jovanovic; Jo Anders Rønneberg; Jörg Tost; Vessela Kristensen
Journal:  Mol Oncol       Date:  2010-04-29       Impact factor: 6.603

3.  Basal-like breast cancer displays distinct patterns of promoter methylation.

Authors:  Ji Shin Lee; Mary Jo Fackler; Jae Hyuk Lee; Chan Choi; Min Ho Park; Jung Han Yoon; Zhe Zhang; Saraswati Sukumar
Journal:  Cancer Biol Ther       Date:  2010-06-18       Impact factor: 4.742

Review 4.  Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.

Authors:  Ashley G Rivenbark; Siobhan M O'Connor; William B Coleman
Journal:  Am J Pathol       Date:  2013-08-27       Impact factor: 4.307

5.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.

Authors:  Adrian P Bracken; Nikolaj Dietrich; Diego Pasini; Klaus H Hansen; Kristian Helin
Journal:  Genes Dev       Date:  2006-04-17       Impact factor: 11.361

Review 6.  Lung cancer early detection and health disparities: the intersection of epigenetics and ethnicity.

Authors:  Lane Lerner; Robert Winn; Alicia Hulbert
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

7.  Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women.

Authors:  Wenyi Qin; Weizhu Zhu; Huidong Shi; John E Hewett; Rachel L Ruhlen; Ruth S MacDonald; George E Rottinghaus; Yin-Chieh Chen; Edward R Sauter
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

8.  GSTP1 promoter hypermethylation is an early event in breast carcinogenesis.

Authors:  Ji Shin Lee
Journal:  Virchows Arch       Date:  2007-05-04       Impact factor: 4.064

9.  Gene promoter hypermethylation in tumors and plasma of breast cancer patients.

Authors:  Young Kyung Bae; Young Ran Shim; Joon Hyuk Choi; Mi Jin Kim; Edward Gabrielson; Soo Jung Lee; Tae Yoon Hwang; Sei One Shin
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

10.  Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.

Authors:  Julie M Wu; Mary Jo Fackler; Marc K Halushka; Diana W Molavi; M Evangeline Taylor; Wei Wen Teo; Constance Griffin; John Fetting; Nancy E Davidson; Angelo M De Marzo; Jessica L Hicks; Dhananjay Chitale; Marc Ladanyi; Saraswati Sukumar; Pedram Argani
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.